002644 佛慈制药
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.0483.8796.5195.8356.998
总资产报酬率 ROA (%)0.7272.6174.3833.9364.512
投入资产回报率 ROIC (%)0.9863.5785.9915.3816.508

边际利润分析
销售毛利率 (%)31.09631.06229.28027.29224.757
营业利润率 (%)8.3847.16013.73213.74219.510
息税前利润/营业总收入 (%)8.0766.59111.80912.47417.881
净利润/营业总收入 (%)6.7955.85710.49011.43816.123

收益指标分析
经营活动净收益/利润总额(%)126.284102.84470.52958.42920.586
价值变动净收益/利润总额(%)-11.544-5.501-0.992-0.766-3.103
营业外收支净额/利润总额(%)-1.755-2.000-9.509-1.3970.141

偿债能力分析
流动比率 (X)2.7092.6492.4032.7602.495
速动比率 (X)1.8881.8581.7342.0701.884
资产负债率 (%)29.29530.04933.19530.8060.335
带息债务/全部投入资本 (%)-10.069-8.628-8.598-12.442-14.002
股东权益/带息债务 (%)-944.317-1,078.540-1,063.428-742.830-657.295
股东权益/负债合计 (%)238.207229.753198.687222.825197.741
利息保障倍数 (X)-49.576-15.412-16.152-11.559-10.794

营运能力分析
应收账款周转天数 (天)105.846103.742110.31395.91799.666
存货周转天数 (天)178.451164.541151.898156.584195.211